FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of biotechnology, namely to the application of the antisense oligonucleotide ISIS 301012 for the long-term reduction of ApoB levels, and can be used in medicine. The method includes the introduction of ISIS 301012 to a subject as a component of a pharmaceutical composition, by the introduction of ISIS 301012 in an induction phase in a dose 210 mg per week for at least 13 weeks, with the further supporting phase, during which ISIS 301012 is introduced in a dose 210 mg per week for the time period which is required, effective and/or tolerable. Each induction dose and each supporting dose independently include more than two injections.
EFFECT: invention makes it possible to attenuate side effects of therapy, namely to reduce erythema in the place of medication introduction.
14 cl, 3 dwg, 21 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| KOBITOLIMOD FOR USE IN TREATMENT OF INFLAMMATORY BOWEL DISEASE | 2018 |
|
RU2766356C2 |
| COMPOSITIONS AND METHODS OF SML2 SPLICING MODULATION IN SUBJECT | 2010 |
|
RU2683772C2 |
| COMPOSITIONS AND METHODS OF MODULATING SMN2 SPLICING IN SUBJECT | 2010 |
|
RU2566724C9 |
| COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT | 2019 |
|
RU2793459C2 |
| CANCER TREATMENT | 2013 |
|
RU2689548C2 |
| APPLICATION OF SUBSTITUTED CYANOPYROLIDINES AND COMBINED PREPARATIONS CONTAINING THEM FOR TREATMENT OF LIPIDEMIA AND ASSOCIATED DISEASES | 2003 |
|
RU2362555C2 |
| METHODS FOR INCREASING HEIGHT OF PEDIATRIC PATIENTS WITH CHOLESTATIC LIVER DISEASE | 2020 |
|
RU2822484C2 |
| USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 CONTENT | 2015 |
|
RU2705991C2 |
| FORMULATION | 2008 |
|
RU2470628C2 |
| METHOD OF TREATING ATHEROSCLEROSIS IN INDIVIDUALS WITH HIGH LEVEL OF TRIGLYCERIDES | 2012 |
|
RU2609200C2 |
